German Tech Holding GmbH & Co. KGaA: German Tech Holding reviews a distinct segregation of existing assets and future life sciences/biotech business in 2027

Frankfurt am Main (pta026/20.10.2026/12:55 UTC+2)

• Spin-off of the heritage VC portfolio, TGS24 and the receivables against SGT Group
• Spun-off assets to be bundled in separate German Startups Group to be formed, and its shares to be allocated to GTH shareholders free of charge
• GTH share listed in the Scale segment to be retained, relieved of realization activities and legal disputes, and focused on the planned, promising investment in Zirnostics
• Development of a proprietary, disruptive, many fold superior compound d for prostate cancer diagnostics by Zirnostics, that has already been clinically tested for years
• Predominant part of the current balance-sheet equity per GTH share to be realized over time within German Startups Group and returned economically to its shareholders

Frankfurt/Main, 20 October 2026 – German Tech Holding (GTH) intends to promptly review with lawyers and tax advisors a distinct corporate legal segregation of its existing investment and further assets from its intended future life sciences/biotech business in 2027. To this end, in particular the heritage VC portfolio, the subsidiary TGS24 Capital Pte. Ltd. (TGS24) and the receivables against the SGT Group including its funds, that have not yet been realized at that point in time are to be transferred to a separate Kommanditgesellschaft auf Aktien, German Startups Group (GSG):

• The GTH share listed in the Scale segment is to be retained and then focused on the planned investment in Zirnostics GmbH (ZNT) and its excellent development prospects. On the basis of its seed investment, GTH intends to assume the role of a lead investor in Zirnostics going forward and to participate in further financing rounds of Zirnostics as well. Zirnostics is preparing a clinical trial for the approval of its disruptive tracer for PSMA-PET/CT imaging in prostate cancer, which is up to 100-fold superior to legacy tracers in terms of tumour-to-background contrast and has already been successfully clinically tested for years in several hundred patients.

• The shares of the newly to be formed GSG are to be held in collective safe custody (Girosammelverwahrung) and transferred to GTH shareholders free of charge in accordance with an allocation ratio still to be determined.

In this way, shareholders shall be able in future to participate separately in the realization of GTH's existing assets within GSG and in the future prospects of GTH, which will then be focused on Zirnostics. With the intended reorganization, GTH's management aims to separate the two economically different areas cleanly from each other and to create an autonomous, clear and transparent profile for each of them, and thereby additional value:

• GSG is to take over the existing heritage VC portfolio currently bundled in German Startups Group VC GmbH (GSGVC), TGS24, the receivables from the SGT Group, including its funds, that have not yet been realized at that point in time, and further assets of GTH to be transferred, realize these gradually and in a value-oriented manner, and distribute the proceeds economically to its shareholders by way of a liquidation distribution. This is to comprise the predominant part of the current balance-sheet equity per GTH share of an estimated 0.93 euros. In this final phase, it is to be relieved of the listing costs in the Scale segment and burdened only to a considerably reduced extent with costs of its general partner for management and assumption of liability.

• GTH, listed in the Scale segment, is by contrast to be relieved of these realization activities and of the existing legal disputes with the SGT Group, and to be aligned entirely with its excellent life sciences/biotech prospects. The estimated net asset value (NAV) per GTH share including non-capitalized assets of more than 1.50 euros is to remain with GTH, with the exception of the predominant part of the current balance-sheet equity per GTH share to be transferred to GSG.

The implementation of the separation is subject to the legal and tax review, necessary preparations under company law and a corresponding resolution of the Annual General Meeting and of the general partner of GTH, which could take place within eight months after the balance-sheet date of the audited annual financial statements as at 31 December 2026.

"In future, we want to offer our shareholders two clearly separated perspectives – the realization of our capitalized assets and the participation in our excellent future opportunities in the life sciences and biotech sector. In this way, we want to create the conditions for both areas to be able to develop their respective potential independently of each other. The listed German Tech Holding is in future to concentrate on Zirnostics and accompany its development as a long-term-oriented seed and lead investor. We are convinced that such a separation would create additional shareholder value," says Christoph Gerlinger, CEO and founder of GTH.

About German Tech Holding

German Tech Holding (GTH) is an investment company founded in 2012 and based in Frankfurt am Main.

During its active years as a leading German venture capital provider under the name German Startups Group, GTH held stakes with great success in, among others, Chrono24, Delivery Hero, Fiagon, Mister Spex, Remerge and Scalable Capital. To this day it holds investments including AuctionTech, SoundCloud and Thinksurance. Through its SaaS-based white-label solution PropNow for digital bidding and offer processes in the real estate market, AuctionTech is the European market leader.

GTH pursues opportunities in the fields of artificial intelligence and life sciences/biotech. Cognicare AI, a spin-off from GTH's investment in the company builder Softmax AI, addresses the structurally growing market for senior care facilities with highly sought-after AI applications. In the field of life science, GTH is examining an investment opportunity in Zirnostics GmbH that has presented itself and has signed a term sheet in this regard. Zirnostics is preparing a clinical trial for the approval of its disruptive tracer for PSMA-PET/CT imaging in prostate cancer, which is up to 100-fold superior to legacy tracers in terms of tumour-to-background contrast and has already been successfully clinically tested for years in several hundred patients.

Securities ID number A1MMEV

ISIN DE000A1MMEV4

Symbol GTH

Further information: germantechholding.com

Investor Relations Contact

Rosenberg Strategic Communications
Mario Groß
m.gross@rosenbergsc.com

Important notice

The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are exclusively authoritative for the currently ongoing public offer. This press release constitutes neither investment advice nor an investment recommendation.

This press release contains forward-looking statements based on current assessments of the management. Such statements are subject to risks and uncertainties, in particular with regard to the completion of the investment transaction, the course of clinical trials, the granting of FDA and EMA approvals under pharmaceutical law and market developments. Actual developments may therefore differ materially. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation.

Disclaimer

This publication is advertising. It constitutes neither an offer to sell nor a solicitation to purchase or subscribe for securities in any jurisdiction, in particular not in the United States of America. An investment decision may be made exclusively on the basis of the information document prepared by the issuer pursuant to Article 1 (4) subpara. 1 lit. db) of the Prospectus Regulation and in accordance with the requirements set out in Annex IX of the Prospectus Regulation, which is published at http://www.germantechholding.com under the heading "For Shareholders" (https://germantechholding.com/index.php/for-shareholders/the-share/) and has been filed with the Federal Financial Supervisory Authority ("BaFin"). BaFin, as the competent national authority, has neither reviewed nor approved this document. Potential investors should read the information document before making an investment decision in order to fully understand the potential risks and opportunities of the decision to invest in the securities.

This publication is not intended, either directly or indirectly, for distribution or dissemination into or within the United States of America (including its territories and possessions, any state of the United States or the District of Columbia) or to publications with a general circulation in the United States of America. The securities are not and will not be registered under the provisions of the U.S. Securities Act of 1933, as amended (the "Securities Act"), and may be sold or offered for purchase in the United States of America only with prior registration under the provisions of the Securities Act as currently in force or, without prior registration, only on the basis of an exemption. The issuer does not intend to register the offer of securities in whole or in part in the United States of America or to conduct a public offering in the United States of America.

Outside Germany, this publication is directed only at, and is intended exclusively for, those persons in member states of the EEA who are "qualified investors" within the meaning of Article 2(e) of the Prospectus Regulation ("qualified investors"). In addition, in the United Kingdom this publication is distributed only to, and is directed only at, those qualified investors (i) who have professional experience in matters relating to investments within the meaning of Article 19 (5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"), (ii) who are high net worth companies within the meaning of Article 49(2)(a) to (d) of the Order, or (iii) who are other persons to whom this publication may lawfully be communicated.

This publication is not an offer to purchase securities in Canada, Japan or Australia.

Forward-looking statements

This announcement contains forward-looking statements based on current assessments of the management. Such statements are subject to risks and uncertainties, in particular with regard to the completion of the investment transaction, the course of clinical trials, the granting of FDA and EMA approvals under pharmaceutical law and market developments. Actual developments may therefore differ materially. This announcement constitutes neither an offer to purchase or subscribe for securities nor investment advice or an investment recommendation. The information document pursuant to Annex IX of Regulation (EU) 2017/1129 and the share purchase application are solely authoritative for the public offer.

(end)

Emitter:	German Tech Holding GmbH & Co. KGaA Humboldtstraße 60B 60318 Frankfurt am Main Germany
Contact Person:	Investor Relations
Phone:	+49 69 348690520
E-Mail:	ir@germantechholding.com
Website:	germantechholding.com
ISIN(s):	DE000A1MMEV4 (Share)
Stock Exchange(s):	Free Market in Dusseldorf, Frankfurt (Scale), Munich, Stuttgart, Tradegate BSX